Bayer applies for Regorafenib authorization to treat liver cancer

FRANKFURT (Reuters) - German drugmaker Bayer on Monday said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.